Voyageur Pharmaceuticals: A Conversation with Founder & CEO Brent Willis

In this episode of the Capital Compounder Show, host Robin Speziale interviews Brent Willis, Founder and CEO of Voyager Pharmaceuticals. They discuss the importance of domestic production of medical imaging drugs, particularly barium contrast, and the discovery of the Frances Creek Project. Brent shares insights into the competitive landscape, market strategies, and the company's innovative approach to iodine production. The conversation also touches on partnerships, market demand, and the challenges faced by entrepreneurs in the pharmaceutical industry.Ownership Disclosure: $VM.v - No

#investing #stocks #personalfinance #wealth #podcast

🎙️WANT TO BE A GUEST? Email me at r.speziale@gmail.com

📰 SIGN UP TO MY FREE NEWSLETTER (JOIN 5,000+): ⁠https://robinspeziale.substack.com⁠

📚 BUY MY BOOKS:

• Market Masters: ⁠https://amzn.to/3Vfexu6⁠

• Capital Compounders: ⁠https://amzn.to/4eYP7bn⁠

• Lessons From The Successful Investor: ⁠https://amzn.to/3Zj2ai1⁠

  
  

𝕏 FOLLOW ME: ⁠https://x.com/RobinSpeziale⁠

💰 DOWNLOAD KOHO AND ADD $50 CASH TO GET $20 FREE: ⁠https://web.koho.ca/referral/UGXXKO6S⁠

***

DISCLAIMER:

This content is for informational purposes only, and should not be construed as offering of investment advice or stock recommendations. This content is based on the author's independent analysis and research and does not guarantee the information's accuracy or completeness. The information contained in this video is subject to change without notice, and the author assumes no responsibility to update the information contained in this video. All information contained herein this video should be independently verified with the sources and companies mentioned. The author is not responsible for errors or omissions. The author does not purport to tell or suggest which investment securities viewers should buy or sell for themselves. Those viewers seeking direct investment advice should consult a qualified, registered, investment professional. The author is not a professional or financial advisor, and does not provide financial advice. Viewers are advised to conduct their own due diligence prior to considering buying or selling any stock. The author will not be liable for any loss or damage caused by a viewer's reliance on information obtained in any of this content. It’s important to understand that investing involves risk, including loss of principal. The author is not engaged in any investor relations agreements with any of the publicly traded companies mentioned. The author does not receive compensation of any kind from any publicly traded companies that are mentioned in any of this content. The author has acquired and may trade shares of some of the companies mentioned through open market transactions and for investment purposes only. Refer to the “author’s ownership disclosure” where applicable. There may be affiliate links to Amazon, and other companies in which the author is compensated if any of the affiliate products are purchased from Amazon.ca/.com or any other companies.